Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 17,781 shares at $0.59 ($11K) on 2019-01-04, disclosed to the SEC on 2019-01-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.59 | 6,205 | $4K | 33.0% |
| 2 | $0.63 | 5,166 | $3K | 29.4% |
| 3 | $0.65 | 6,410 | $4K | 37.6% |
| Total | $0.62 avg | 17,781 | $11K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |